• On 20 April 2026, Arcus Biosciences and Gilead Sciences discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee deemed the domvanalimab plus zimberelimab and chemotherapy arm futile, while zimberelimab plus chemotherapy showed overall survival in line with pembrolizumab plus chemotherapy.
• Arcus also disclosed that Gilead will let certain option rights lapse in July 2026, narrowing access to Arcus’s early pipeline while retaining time-limited options on select programs, which shifts how Arcus may fund and prioritize future research.
• We’ll now examine how the STAR-121 discontinuation and Gilead’s reduced option rights could reshape Arcus Biosciences’ investment narrative and outlook.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Arcus Biosciences Investment Narrative Recap

To own Arcus Biosciences today, you need to believe its future rests more on casdatifan and the broader pipeline than on domvanalimab in lung cancer. The STAR-121 and EDGE-Lung discontinuations weaken the TIGIT story and remove a near term lung cancer catalyst, while Gilead’s narrower option rights highlight funding and partnership risk as Arcus advances expensive late stage programs without profitable products.

The 20 April 2026 update on Gilead’s decision to let some option rights lapse is especially relevant here, because it tightens Arcus’s access to external capital for early programs even as the company retains key partnered options like AB801 and AB598. This shift increases the importance of upcoming casdatifan readouts as potential value drivers, while making Arcus’s cash runway and any future financing moves more central to the investment case.

Yet, against this backdrop of promising data, the risk that Gilead’s reduced involvement may further expose Arcus’s funding dependence is something investors should be aware of...

Arcus Biosciences’ narrative projects $178.6 million in revenue and $26.5 million in earnings by 2029.

Uncover how Arcus Biosciences' forecasts yield a $34.20 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Before this news, the most cautious analysts were already modeling revenue shrinking about 5.2% annually and persistent losses, highlighting how a Gilead pullback and TIGIT setback could reinforce a much more pessimistic view than the consensus.

Explore 3 other fair value estimates on Arcus Biosciences - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arcus Biosciences research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Arcus Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcus Biosciences' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.